delavirdine has been researched along with tipranavir in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M | 1 |
| Chong, KT; Dueweke, TJ; Gorman, RR; Hinshaw, RR; Ho, DD; Markowitz, M; Mo, H; Pagano, PJ; Poppe, SM; Slade, DE; Tarpley, WG; Thaisrivongs, S | 1 |
1 review(s) available for delavirdine and tipranavir
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
2 other study(ies) available for delavirdine and tipranavir
| Article | Year |
|---|---|
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries | 2023 |
Antiviral activity of the dihydropyrone PNU-140690, a new nonpeptidic human immunodeficiency virus protease inhibitor.
Topics: Anti-HIV Agents; Antiviral Agents; Cells, Cultured; Delavirdine; Drug Combinations; Drug Evaluation, Preclinical; Drug Synergism; Genotype; HIV Protease Inhibitors; HIV-1; Humans; Indoles; Piperazines; Pyridines; Pyrones; Reverse Transcriptase Inhibitors; Sulfonamides; Virus Replication; Zidovudine | 1997 |